CMS picks Lilly’s Trulicity for third round of Medicare negotiations
Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act.
Eli Lilly’s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the ...
⚠️ 风险分析 中
摘要：礼来Trulicity被纳入医保谈判，面临价格与市场准入风险。
影响：药品价格可能因政府谈判而下降，影响企业营收与利润，并可能引发市场准入限制或合规审查。
建议：密切关注谈判进展，评估定价策略，并准备应对可能的合规与市场变化。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.